227 related articles for article (PubMed ID: 25472643)
21. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
22. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Meyers MO; Klauber-Demore N; Ollila DW; Amos KD; Moore DT; Drobish AA; Burrows EM; Dees EC; Carey LA
Ann Surg Oncol; 2011 Oct; 18(10):2851-7. PubMed ID: 21442348
[TBL] [Abstract][Full Text] [Related]
23. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
24. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
[TBL] [Abstract][Full Text] [Related]
25. HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.
Jia H; Jia W; Yang Y; Li S; Feng H; Liu J; Rao N; Jin L; Wu J; Gu R; Zhu L; Chen K; Deng H; Zeng Y; Liu Q; Song E; Su F
World J Surg Oncol; 2014 Sep; 12():289. PubMed ID: 25241216
[TBL] [Abstract][Full Text] [Related]
26. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
[TBL] [Abstract][Full Text] [Related]
27. Is a higher boost dose of radiation necessary after breast-conserving therapy for patients with breast cancer with final close or positive margins?
Sadek BT; Homayounfar G; Abi Raad RF; Niemierko A; Shenouda MN; Keruakous AR; Specht MC; Taghian AG
Breast Cancer Res Treat; 2015 Nov; 154(1):71-9. PubMed ID: 26420403
[TBL] [Abstract][Full Text] [Related]
28. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
Panoff JE; Hurley J; Takita C; Reis IM; Zhao W; Sujoy V; Gomez CR; Jorda M; Koniaris L; Wright JL
Breast Cancer Res Treat; 2011 Aug; 128(3):899-906. PubMed ID: 21475999
[TBL] [Abstract][Full Text] [Related]
29. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
30. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.
Hattangadi-Gluth JA; Wo JY; Nguyen PL; Abi Raad RF; Sreedhara M; Niemierko A; Freer PE; Georgian-Smith D; Bellon JR; Wong JS; Smith BL; Harris JR; Taghian AG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1185-91. PubMed ID: 21601377
[TBL] [Abstract][Full Text] [Related]
31. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
32. Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.
Wang J; Luo J; Jin K; Wang X; Yang Z; Ma J; Mei X; Wang X; Zhou Z; Yu X; Chen X; Guo X
Cancer Med; 2020 Apr; 9(7):2427-2434. PubMed ID: 32048817
[TBL] [Abstract][Full Text] [Related]
33. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
Valachis A; Mamounas EP; Mittendorf EA; Hayashi N; Ishitobi M; Natoli C; Fitzal F; Rubio IT; Tiezzi DG; Shin HC; Anderson SJ; Hunt KK; Matsuda N; Ohsumi S; Totomi A; Nilsson C
Cancer; 2018 Jul; 124(14):2923-2930. PubMed ID: 29723396
[TBL] [Abstract][Full Text] [Related]
35. Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.
van der Leij F; van Werkhoven E; Bosma S; Linn SC; Rutgers EJ; van de Vijver MJ; Bartelink H; Elkhuizen PHM; Scholten A
Breast; 2016 Dec; 30():19-25. PubMed ID: 27587341
[TBL] [Abstract][Full Text] [Related]
36. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach.
Beadle BM; Woodward WA; Tucker SL; Outlaw ED; Allen PK; Oh JL; Strom EA; Perkins GH; Tereffe W; Yu TK; Meric-Bernstam F; Litton JK; Buchholz TA
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):734-44. PubMed ID: 18707822
[TBL] [Abstract][Full Text] [Related]
37. Impact of de-escalating systemic therapy guided by 21-gene assay on locoregional recurrence after partial-breast irradiation.
Sato K; Takeda N; Fuchikami H; Natsume N; Kato M; Okawa T
Brachytherapy; 2023; 22(3):381-388. PubMed ID: 36894345
[TBL] [Abstract][Full Text] [Related]
38. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
39. Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients.
Bantema-Joppe EJ; van den Heuvel ER; de Munck L; de Bock GH; Smit WG; Timmer PR; Dolsma WV; Jansen L; Schröder CP; Siesling S; Langendijk JA; Maduro JH
Breast Cancer Res Treat; 2013 Aug; 140(3):577-85. PubMed ID: 23912958
[TBL] [Abstract][Full Text] [Related]
40. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.
Albert JM; Gonzalez-Angulo AM; Guray M; Sahin A; Strom EA; Tereffe W; Woodward WA; Tucker SL; Hunt KK; Hortobagyi GN; Buchholz TA
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1296-302. PubMed ID: 20472353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
